failure with reduced ejection fraction (HFrEF). Results in prediabetes have revealed a significant preventative effect (58% risk reduction) by lifestyle intervention on the progression of disease to clinical diabetes, 14 a positive effect on the development of microvascular complications (e.g. nephropathy in type 2 diabetes, 31% risk reduction) 15 and a reduction of recurrent hospitalization in HFrEF (11% risk reduction). 16 However, effects in these large trials were significantly less than expected from the results of smaller pilot studies, and failed to show an expected reduction of macrovascular complications or mortality in type 2 diabetes 15 or a reduction of mortality in HFrEF. 16 These less-than-expected effects can be readily explained by low adherence to intervention programmes of weight reduction and/or increment of physical activity. 15, 16 Therefore, as outlined in the current position paper, 1 improving adherence to lifestyle intervention programs is crucial and clinical effects are overwhelming when patients adhere to lifestyle interventions. [17] [18] [19] The current position paper has listed the gaps for research in preventive cardiology. 1 They include the need for re-evaluation and recalibration of the current risk scores by adding genetics, omics-analyses, cardiac biomarkers, vascular functional parameters or morphological analyses of atherosclerotic plaques -for example, by calcium score. Moreover, the equivocal role of alcohol, stress and dosage of supplementation (e.g. omega 3 fatty acids) have been outlined. 1 In order to improve established risk scores, a detailed battery of questionnaires, genetics, biochemical analyses and imaging is currently applied in large cohorts involving 200,000 individuals (German National Cohort) 20 or in the UK Biobank Study involving >500,000 individuals. 21, 22 This will certainly improve the definition of individual risk beyond the established cardiovascular risk factors and first results have been presented. [21] [22] [23] However, importantly, this knowledge will have to be integrated into lifestyle preventive strategies. Characterization of ''basic'' biomarkers with prognostic potential to predict high-risk patients will have to be added by the identification of ''modifiable biomarkers'', which characteristically change by intervention strategies and predict efficacy of intervention. Optimally, assessment of these parameters, either as single or in combination of several parameters, will predict the most effective intervention with the highest probability of success in reducing cardiovascular morbidity and mortality ( Figure 1 ). This preventative approach is not limited to lifestyle intervention, but also applies to pharmacological treatment. This ''Personalized Prevention'' strategy can be applied in primary and secondary prevention and will hopefully significantly reduce the burden of cardiovascular disease, the mission of the European Society of Cardiology.
Therefore, the overall perspective of a future preventive cardiology research endeavour is translational research along the pathophysiological pathways from cardiovascular risk factors to pathological manifestation within the coronary circulation and myocardium, also verifying strategies of different lifestyle interventions. To achieve this, research strategies will have to build on two main pillars that will closely interact regarding the intervention concept: (a) basic research -for example, in animal models investigating molecular mechanisms of lifestyle intervention on cardiovascular pathophysiology; and (b) clinical research focusing on randomized controlled lifestyle intervention studies in humans. Both strategies will have to be aligned according to similar intervention modes in order to answer the questions of preventative mechanisms by lifestyle intervention. One example for this approach is the OptimEx trial 24, 25 in myocardial diastolic dysfunction and heart failure with preserved ejection fraction, in which different modes of exercise intensity are applied in similar ways in animals and humans, also assessing biomarkers of risk as well as efficacy of intervention. Furthermore, novel technologies of monitoring physiological and biochemical parameters will have to be further developed and included 26 -for example, from wearables assessing gait speed and heart rate to implanted subcutaneous devices assessing biochemical parameters. This information may then be collected in large cohorts and linked to clinical outcomes. These strategies may collect data from large cohorts within a relatively short period of time, which has been demonstrated very recently in monitoring atrial fibrillation by smart watches (inclusion of >400,000 individuals within eight months). 27 The exponential development within the field of technology in assessing novel biomarkers, detailed physiological data and behaviour in large cohorts will definitely foster knowledge and implementation strategies in preventive cardiology. However, there is a clear demand for conducting large international, multi-centre randomized controlled trials including personalized prevention strategies as well as new technology, also focussing on long-term adherence and patient population implementation. The current update of the primary prevention position statement 1 is a call for action.
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